Cost-Effectiveness of the Implantable Cardioverter Defibrillator
Tóm tắt
Many clinicians and policymakers are concerned whether use of the implantable defibrillator (ICD) is justified in view of its high cost. Three randomized trials of the ICD have reported economic outcomes. Each trial found a large difference in cost between patients assigned to an ICD versus patients assigned to conventional therapy that persisted over three to six years of follow-up. Each trial also found better survival among ICD patients, and calculated ICD cost-effectiveness (CE) ratios between $27,000 per life year added and $139,000 per life year added. The variability in the cost-effectiveness ratios among trials is mainly due to variability in the years of life added by the ICD among the trials and, by extension, among patient subgroups. A rough rule of thumb is that the ICD will be economically attractive when it prolongs mean survival by six months or more, which is attainable in higher risk patient subgroups.
Tài liệu tham khảo
Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials. Ann Intern Med 2003;138:512–514.
Zipes DP. Implantable cardioverter-defibrillator: A Volkswagen or a Rolls Royce. How much will we pay to save a life? Circulation 2001;103:1372–1374.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
Buxton AE. The clinical use of implantable cardioverter defibrillators: Where are we now? Where should we go? Ann Intern Med 2003;138:512–514.
Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002;106:516–520.
Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine. Part II. Circulation 2002;106:626–630.
Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, Zou KH, Moss AJ, MADIT Investigators. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation 1998;97:2129–2135.
Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S, Brodsky M, Powell J, Marchant C, Jennings C, Akiyama T. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias. Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy. Circulation 2002;105:2049–2057.
O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, Roberts RS, Gent M. Cost-effectiveness of the implantable cardioverter defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001;103:1416–1421.
Bardy GH. The sudden cardiac death-heart failure trial (SCD-HeFT). In: Woosley RL, ed. Arrhythmia Treatment and Therapy. Evaluation of Clinical Trial Evidence. New York: Marcel Dekker, Inc.; 2000.
Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000;21:2071–2078.
Sheldon R, O'Brien BJ, Blackhouse G, Georee R, Mitchell B, Klein G, Roberts RS, Gent M, Connolly SJ. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator. The Canadian Implantable Defibrillator Study. Circulation 2001;104:1622–1626.
Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on costeffectiveness of the implantable cardioverter defibrillator. Am Heart J 2002;144:440–448.
Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Potential costeffectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001;135:870–883.